Andrew Tsai
Stock Analyst at Jefferies
(4.82)
# 448
Out of 5,028 analysts
162
Total ratings
56.3%
Success rate
26.3%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reiterated: Buy | $255 | $223.59 | +14.05% | 11 | Oct 5, 2026 | |
| MRNA Moderna | Reiterated: Hold | $60 → $150 | $203.21 | -26.18% | 9 | Sep 22, 2026 | |
| DYN Dyne Therapeutics | Reiterated: Buy | $42 → $50 | $15.44 | +223.83% | 6 | Sep 8, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $110 | $66.14 | +66.31% | 12 | Aug 31, 2026 | |
| NERV Minerva Neurosciences | Upgraded: Buy | $5 → $10 | $3.33 | +200.75% | 3 | Aug 14, 2026 | |
| ANRO Alto Neuroscience | Reiterated: Buy | $35 → $40 | $24.01 | +66.60% | 9 | Aug 13, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $65 | $36.23 | +79.41% | 6 | Aug 13, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $380 | $177.08 | +114.59% | 4 | Aug 11, 2026 | |
| PRAX Praxis Precision Medicines | Reiterated: Buy | $550 | $283.56 | +93.96% | 8 | Jun 30, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $18 | $11.60 | +55.17% | 2 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $145 | $49.79 | +191.22% | 1 | Apr 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $65 → $100 | $37.57 | +166.17% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $30 | $17.49 | +71.53% | 12 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7.5 | $4.58 | +63.76% | 1 | Dec 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $0.9 | $0.2632 | +241.95% | 5 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $25.32 | +18.48% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $32 | $9.28 | +245.01% | 1 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $4.20 | +138.10% | 7 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $2.5 → $3 | $2.61 | n/a | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $0.85 | $1.74 | n/a | 2 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8.5 | $4.78 | n/a | 7 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $42.76 | n/a | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $35 | $32.19 | n/a | 3 | Dec 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $0.5 | $5.58 | n/a | 9 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $75 → $13 | $3.48 | n/a | 4 | Sep 16, 2024 |
Biogen
Oct 5, 2026
Reiterated: Buy
Price Target: $255
Current: $223.59
Upside: +14.05%
Moderna
Sep 22, 2026
Reiterated: Hold
Price Target: $60 → $150
Current: $203.21
Upside: -26.18%
Dyne Therapeutics
Sep 8, 2026
Reiterated: Buy
Price Target: $42 → $50
Current: $15.44
Upside: +223.83%
BridgeBio Pharma
Aug 31, 2026
Reiterated: Buy
Price Target: $110
Current: $66.14
Upside: +66.31%
Minerva Neurosciences
Aug 14, 2026
Upgraded: Buy
Price Target: $5 → $10
Current: $3.33
Upside: +200.75%
Alto Neuroscience
Aug 13, 2026
Reiterated: Buy
Price Target: $35 → $40
Current: $24.01
Upside: +66.60%
Definium Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $65
Current: $36.23
Upside: +79.41%
Axsome Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $380
Current: $177.08
Upside: +114.59%
Praxis Precision Medicines
Jun 30, 2026
Reiterated: Buy
Price Target: $550
Current: $283.56
Upside: +93.96%
COMPASS Pathways
May 14, 2026
Reiterated: Buy
Price Target: $18
Current: $11.60
Upside: +55.17%
Apr 12, 2026
Initiated Coverage: Buy
Price Target: $145
Current: $49.79
Upside: +191.22%
Mar 9, 2026
Rated: Buy
Price Target: $65 → $100
Current: $37.57
Upside: +166.17%
Jan 12, 2026
Reiterated: Buy
Price Target: $35 → $30
Current: $17.49
Upside: +71.53%
Dec 31, 2025
Reiterated: Hold
Price Target: $7.5
Current: $4.58
Upside: +63.76%
Dec 17, 2025
Downgraded: Hold
Price Target: $15 → $0.9
Current: $0.2632
Upside: +241.95%
Nov 24, 2025
Reiterated: Buy
Price Target: $30
Current: $25.32
Upside: +18.48%
Nov 21, 2025
Initiated Coverage: Buy
Price Target: $32
Current: $9.28
Upside: +245.01%
Nov 11, 2025
Reiterated: Buy
Price Target: $10
Current: $4.20
Upside: +138.10%
Aug 8, 2025
Reiterated: Hold
Price Target: $2.5 → $3
Current: $2.61
Upside: n/a
Aug 6, 2025
Reiterated: Hold
Price Target: $3 → $0.85
Current: $1.74
Upside: n/a
Mar 26, 2025
Reiterated: Buy
Price Target: $8.5
Current: $4.78
Upside: n/a
Mar 12, 2025
Reiterated: Buy
Price Target: $40
Current: $42.76
Upside: n/a
Dec 7, 2024
Rated: Buy
Price Target: $35
Current: $32.19
Upside: n/a
Sep 18, 2024
Rated: Hold
Price Target: $3 → $0.5
Current: $5.58
Upside: n/a
Sep 16, 2024
Upgraded: Buy
Price Target: $75 → $13
Current: $3.48
Upside: n/a